Grifols

We successfully hosted the sixth edition of the Barcelona MBA Day, providing MBA students with an exclusive look into our operations and culture. As part of Barcelona Global's initiative to position Barcelona as a leading hub for innovation and industry, this event highlighted Grifols’ vital role in the local economy and our dedication to attracting top talent. Throughout the day, students had the opportunity to tour our facilities, learn about the company's mission and products, and network with industry professionals. This provided valuable insights into the biopharma industry and potential career paths. We are thrilled to be part of this initiative that strengthens Barcelona’s reputation and nurtures future leaders. #GrifolsTalent #MBADay

We are pleased to announce that our S&P Global ESG score has reached an all-time high of 70 points, marking a 7-points improvement compared to last year’s results. As we continue to enhance our sustainability performance, this achievement is the result of collective efforts across the entire company and reaffirms the strength of our strategy and shared commitment to sustainability. Learn more here 👉 http://spr.ly/6046qzy1i #SustainableFuture #CorporateResponsibility #ESG

As a pioneering global healthcare company, we are dedicated to advancing healthcare through cutting-edge research and development. Every day, more than 1,200 researchers work across our 14 international R&D hubs to explore new ways to discover new treatments that may make a difference for patients' lives. From our origins in plasma-based solutions to our next-generation diagnostic tools, our innovation never stops. Today we want you to meet Alexander Kovach, one of our talented researchers at Research Triangle Park, N.C., U.S., as he dives into groundbreaking work on immunoglobulins (Ig). His research is part of our continued commitment to exploring the potential of Ig therapies. #GrifolsTeam #Immunology #research

As #IPAW2024 comes to an end, we would like to highlight how plasma-derived medicines are essential far beyond rare and chronic diseases. Hospitals and clinics use these treatments every day for various common and emergency situations, such as animal bites, burns, shock, trauma, rhesus (Rh) incompatibility during pregnancy, and more. In December 2023, the European Medicines Agency (EMA) recognized the vital importance of these medicines by listing almost all of them on the European Union’s first Critical Medicines List. Through Grifols’ Global Plasma Self-sufficiency Program, we are establishing paradigm-changing agreements around the world that support countries and regions in their efforts to ensure their patient populations have the plasma treatments they absolutely depend on. #PlasmaConnectsUs

We're excited to join the global community in celebrating World Mental Health Day. At Grifols, mental health is a priority, and we are dedicated to fostering a supportive and healthy work environment. As part of this commitment, we have implemented a comprehensive Mental Health Policy and a Wellbeing Plan, where mental health serves as a key pillar. We believe that supporting the mental well-being of our employees is not only essential for their personal and professional growth, but also vital to our overall success as a company. #WeAreGrifols #WorldMentalHealthDay #TogetherForMentalHealth

Continuing with the celebration of the #IPAW2024, we would like to highlight the uniqueness of plasma-derived medicines. Unlike other pharmaceuticals, the production of plasma-derived medicines starts with a biological material, human plasma. It can take up to 12 months from plasma donation to the patient receiving a plasma-derived medicine. This is due to the long, complex and highly regulated manufacturing process required to produce these high-quality medicines. Learn more on the importance of plasma 👉 http://spr.ly/6049UyF5t #PlasmaConnectsUs

⚽ It is an honor to sponsor, for the fourth year in a row, UEFA's women's football competitions. We firmly believe that sports are one of the most powerful platforms for promoting gender equality. Every female athlete dreaming big inspires other women and girls working to achieve extraordinary goals. As the UEFA Women's Champions League season 24/25 starts the group stage, sixteen teams are aiming to get to the final in Lisbon. We wish the best of luck to all players. Their ambition and strength pave the way for new opportunities for all. #GrifolsSocialImpact #UWCL

We are excited to kick off International Plasma Awareness Week #IPAW2024, a week dedicated to raising global awareness about plasma collection, recognizing the contributions of plasma donors and increasing understanding about plasma-derived medicines. Millions of people around the globe with rare and chronic diseases as well as others facing trauma and medical emergencies rely on plasma-derived medicine. The number of patients in need has risen in recent years. These medicines are only possible because of plasma donations. Donors’ generosity makes a world of difference. We want you to meet some of these incredible heroes. #PlasmaConnectsUs

We are excited to announce the launch of the first edition of the Strategy Program, a premier global initiative designed to enhance leadership expertise with a strategic approach. This 9-month program is set to shape the future of our organization by preparing individuals for key senior leadership roles.     In collaboration with Esade Business School, participants will engage in a rigorous curriculum that combines theoretical knowledge with practical application to build high-performing, inclusive teams, ensuring they are well-equipped to lead our organization into the future. This program underscores Grifols' commitment to nurturing talent and driving excellence at every level. #WeAreGrifols #LeadingTheFuture #businessstrategy

We are pleased to announce that GigaGen, a subsidiary of Grifols, has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services (HHS) to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNTs) and a second biothreat of interest to the agency. The contract, worth up to $135.2M, will support the creation, manufacturing and initial clinical development of a drug product that targets the biothreats of both programs. For more information, see the press release 👉 http://spr.ly/6042Uruj8 #WeAreInnovation #biothreats